Want to see IN:BAJAJHCARE full AI Analyst Report?
Top Page
Bajaj Healthcare Ltd
(BAJAJHCARE)
Select Model
Select Model
Rating:48Neutral
Price Target:
₹347.00
▼(-17.08% Downside)
Action:Reiterated
Date:07/23/26
The score is held back primarily by inconsistent profitability and weak free cash flow despite improved leverage and a modest FY2026 revenue recovery. Technicals are neutral-to-weak with the stock below key moving averages, and valuation is stretched due to a high P/E and minimal dividend yield.
Positive Factors
Revenue Recovery
The return to revenue growth indicates renewed demand across the company’s pharmaceutical activities after a weaker period. If maintained, improving sales can support better capacity utilization, broaden customer contribution, and provide a foundation for rebuilding sustainable earnings over the next several quarters.
Negative Factors
Sharp Net Margin Compression
The steep decline in net margin shows that revenue recovery has not yet translated into dependable bottom-line profitability. Persistently thin earnings leave less room to absorb cost or financing volatility, weaken earnings quality, and make sustained profit improvement important for the business outlook.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Recovery
The return to revenue growth indicates renewed demand across the company’s pharmaceutical activities after a weaker period. If maintained, improving sales can support better capacity utilization, broaden customer contribution, and provide a foundation for rebuilding sustainable earnings over the next several quarters.
Read all positive factors
Bajaj Healthcare Ltd (BAJAJHCARE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹10.89B
Dividend Yield0.46%
Average Volume (3M)11.34K
Price to Earnings (P/E)59.6
Beta (1Y)1.38
Revenue Growth12.27%
EPS Growth-62.46%
CountryIN
Employees1,019
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)5.39
Shares Outstanding33,665,160
10 Day Avg. Volume13,418
30 Day Avg. Volume11,339
Financial Highlights & Ratios
PEG Ratio-0.93
Price to Book (P/B)1.72
Price to Sales (P/S)1.50
P/FCF Ratio-149.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bajaj Healthcare Ltd Business Overview & Revenue Model
Company Description
Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in...
How the Company Makes Money
Bajaj Healthcare makes money primarily by manufacturing and selling pharmaceutical products and related materials to customers in the pharma supply chain. Its key revenue streams are: (1) Sales of active pharmaceutical ingredients (APIs) and inter...
Bajaj Healthcare Ltd Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
63
Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.28B | 6.11B | 5.43B | 4.73B | 6.46B | 6.79B |
| Gross Profit | 2.36B | 2.04B | 1.71B | 2.14B | 1.33B | 1.84B |
| EBITDA | 828.71M | 787.05M | 1.02B | 406.24M | 1.22B | 1.20B |
| Net Income | 176.30M | 157.66M | 394.95M | -837.93M | 430.24M | 713.86M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 9.23B | 8.33B | 7.65B | 9.01B | 7.21B |
| Cash, Cash Equivalents and Short-Term Investments | 379.87M | 379.87M | 44.51M | 29.29M | 192.29M | 19.75M |
| Total Debt | 0.00 | 2.49B | 2.23B | 3.33B | 4.15B | 2.57B |
| Total Liabilities | -5.33B | 3.90B | 3.67B | 4.87B | 5.34B | 3.93B |
| Stockholders Equity | 5.33B | 5.33B | 4.66B | 2.78B | 3.68B | 3.28B |
Cash Flow | ||||||
| Free Cash Flow | 392.01M | -61.26M | -173.16M | 620.08M | -1.46B | -786.19M |
| Operating Cash Flow | 501.85M | 372.23M | -57.78M | 922.94M | -223.24M | 6.86M |
| Investing Cash Flow | -198.00M | -480.91M | -153.21M | -112.45M | -934.27M | -747.98M |
| Financing Cash Flow | -210.12M | 455.00M | 215.28M | -965.96M | 1.31B | 618.46M |
Bajaj Healthcare Ltd Technical Analysis
Negative
418.50
Price Trends
328.18
Negative
322.52
Negative
336.59
Negative
Market Momentum
0.19
Positive
40.96
Neutral
9.16
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BAJAJHCARE, the sentiment is Negative. The current price of 418.5 is above the 20-day moving average (MA) of 331.96, above the 50-day MA of 328.18, and above the 200-day MA of 336.59, indicating a bearish trend. The MACD of 0.19 indicates Positive momentum. The RSI at 40.96 is Neutral, neither overbought nor oversold. The STOCH value of 9.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BAJAJHCARE.
Bajaj Healthcare Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ₹15.27B | 34.19 | ― | 1.72% | 3.87% | -25.38% | |
78 Outperform | ₹11.66B | 12.04 | ― | 0.31% | 10.20% | 11.70% | |
70 Outperform | ₹22.53B | 26.36 | ― | 0.42% | 0.44% | 48.60% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ₹10.51B | 26.09 | ― | 0.44% | -12.75% | ― | |
49 Neutral | ₹6.96B | 11.39 | ― | 1.20% | 3.63% | 24.22% | |
48 Neutral | ₹10.89B | 59.55 | ― | 0.46% | 12.27% | -62.46% |
* General Sector Average
IN:BAJAJHCARE
Bajaj Healthcare Ltd
323.40
-162.15
-33.40%
IN:JAGSNPHARM
Jagsonpal Pharmaceuticals Ltd.
231.55
15.97
7.41%
IN:LINCOLN
Lincoln Pharmaceuticals Ltd
582.15
55.99
10.64%
IN:SYNCOMF
Syncom Formulation (India) Ltd.
23.97
7.60
46.44%
IN:THEMISMED
Themis Medicare Limited
114.10
-16.22
-12.45%
IN:WANBURY
Wanbury Limited
199.00
-56.60
-22.14%
Bajaj Healthcare Ltd Corporate Events
Bajaj Healthcare Dispatches 33rd AGM Notice and FY26 Annual Report
Aug 30, 2026
Bajaj Healthcare Ltd has announced that it has dispatched the notice for its 33rd Annual General Meeting along with the annual report for the financial year 2025-26 to shareholders. The company has also published related e-voting information in th...
Bajaj Healthcare Releases Q1 FY27 Earnings Call Transcript
Jul 27, 2026
Bajaj Healthcare Limited has submitted to the stock exchanges the official transcript of its Q1 FY27 earnings conference call, detailing the financial performance for the quarter ended June 30, 2026. The call, held on July 21, 2026, featured Manag...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.